San Diego, CA -- (SBWIRE) -- 04/18/2017 -- TherapeuticsMD Inc is under investigation concerning possible violations of securities laws. The investigation was announced for investors in NYSEMKT:TXMD shares in connection certain financial statements made by TherapeuticsMD Inc.

Investors who purchased shares of TherapeuticsMD Inc (NYSEMKT:TXMD), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether certain statements by TherapeuticsMD Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Boca Raton, FL based TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. TherapeuticsMD Inc is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. TherapeuticsMD Inc reported that its annual Total Revenue declined from $20.14 million in 2015 to $19.36 million in 2016 and that its Net Loss increased from $85.08 million in 2015 to $89.88 million in 2016.

On April 10, 2017, TherapeuticsMD Inc announced receipt of a letter from the U.S. Food and Drug Administration ("FDA"stating that its ongoing review of the Company's New Drug Application (NDA) for TX-004HR has discovered "deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.

Shares of TherapeuticsMD Inc (NYSEMKT:TXMD) declined on April 17, 2017 to $5.14 per share.

Those who purchased shares of TherapeuticsMD Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com